贝利尤单抗治疗SLE后低疾病活动度与临床缓解的预测因素
本研究基于BLISS-52与BLISS-76两项临床试验中接受贝利尤单抗10 mg/kg治疗的563例SLE患者,采用logistic回归评估基线因素对第52周达到LLDAS或cSLEDAI-2K=0的预测作用。结果显示基线器官损伤(SDI>0或>1)负向预测低疾病活动度与临床缓解,抗dsDNA阳性可能提高临床缓解概率。
要点
- 基线SDI>0与>1分别负向预测第52周LLDAS达成。
- 基线SDI>1负向预测cSLEDAI-2K=0,皮肤损伤是主要驱动因素。
- 抗dsDNA阳性与泼尼松等效剂量≤7.5 mg/d条件下临床缓解概率升高相关。
核心结论
- 贝利尤单抗在治疗前器官损伤有限或无损伤的SLE患者中可能更有效诱导低疾病活动度与临床缓解。
- 抗dsDNA滴度阳性且激素用量受限的患者可能更易达到临床缓解。
研究设计与样本
- 基于BLISS-52与BLISS-76临床试验,纳入接受贝利尤单抗10 mg/kg的SLE患者563例。
- 采用logistic回归评估基线因素对第52周LLDAS或cSLEDAI-2K=0的预测作用,器官损伤用SLICC/ACR损伤指数(SDI)评估。
主要发现
- SDI>0负向预测LLDAS达成(OR 0.44;95%CI 0.22, 0.90;P=0.024)。
- SDI>1负向预测LLDAS主要条件即SLEDAI-2K≤4且无肾脏活动、胸膜炎、心包炎或发热(OR 0.46;95%CI 0.27, 0.77;P=0.004),认知障碍/精神病主要解释该关联。
- SDI>1预测未能达到cSLEDAI-2K=0(OR 0.53;95%CI 0.30, 0.94;P=0.030),皮肤损伤主要驱动该关联。
- 抗dsDNA阳性提高达到cSLEDAI-2K=0的概率(OR 1.82;95%CI 1.08, 3.06;P=0.025)。
- 心血管损伤降低达到cSLEDAI-2K=0的概率(OR 0.13;95%CI 0.02, 0.97;P=0.047),该分析同时限定每日泼尼松等效剂量≤7.5 mg。
关键数值与推荐
- 低疾病活动度定义为Lupus Low Disease Activity State(LLDAS)。
- 临床缓解定义为临床cSLEDAI-2K=0。
- 器官损伤采用SLICC/ACR Damage Index(SDI)评估。
临床怎么用
- 启始贝利尤单抗前评估基线器官损伤(SDI)有助于预判第52周低疾病活动度与临床缓解的可能性。
- 对抗dsDNA阳性且激素用量≤7.5 mg/d等效剂量的患者,可预期更高的临床缓解概率。
局限性
- 本文为基于BLISS-52与BLISS-76临床试验数据的分析,摘要未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To identify predictors of low disease activity and clinical remission following belimumab treatment in SLE. METHODS: SLE patients who received belimumab 10 mg/kg (N = 563) in the BLISS-52 and BLISS-76 clinical trials were surveyed. The performance of baseline factors in predicting attainment of low disease activity (defined as Lupus Low Disease Activity State) or clinical remission [defined as clinical (c)SLEDAI-2K = 0] at week 52 from treatment initiation was evaluated using logistic regression. Organ damage was assessed using the SLICC/ACR Damage Index (SDI). RESULTS: We demonstrated a negative impact of established organ damage on attainment of Lupus Low Disease Activity State [SDI > 0; odds ratio (OR): 0.44; 95% CI 0.22, 0.90; P = 0.024] and the primary Lupus Low Disease Activity State condition, i.e. SLEDAI-2K ⩽ 4 with no renal activity, pleurisy, pericarditis or fever (SDI > 1; OR: 0.46; 95% CI 0.27, 0.77; P = 0.004); cognitive impairment/psychosis was found to mainly account for the latter association. Baseline SDI scores > 1 predicted failure to attain cSLEDAI-2K = 0 (OR: 0.53; 95% CI 0.30, 0.94; P = 0.030), with cutaneous damage mainly driving this association. Anti-dsDNA positivity increased (OR: 1.82; 95% CI 1.08, 3.06; P = 0.025) and cardiovascular damage reduced (OR: 0.13; 95% CI 0.02, 0.97; P = 0.047) the probability of attaining cSLEDAI-2K = 0 along with a daily prednisone equivalent intake restricted to ⩽7.5 mg. CONCLUSION: Belimumab might be expected to be more efficacious in inducing low disease activity and clinical remission in SLE patients with limited or no organ damage accrued prior to treatment initiation. Patients with positive anti-dsDNA titres might be more likely to achieve clinical remission along with limited or no CS use.
引用
- Parodis I, Johansson P, Gomez A, et al. Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus. Rheumatology (Oxford). 2019. PMID: 31157891. doi:10.1093/rheumatology/kez191
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。